Physician profile

Meher Burki

Hematology & Oncology · West Chester, PA

NPI 1184877813

$3,850.00

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$1,725.00
Consulting Fee$1,080.00
Food and Beverage$64.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Cti Biopharma Corp. $1,725.00 2023 Vonjo
Astrazeneca Pharmaceuticals LP $1,080.00 2023-2024 Imfinzi
Daiichi Sankyo INC. $550.00 2022
Servier Pharmaceuticals LLC $318.52 2021
Pharmacyclics LLC, An Abbvie Company $163.84 2021-2023 Imbruvica
Gilead Sciences, INC. $11.92 2021
Clovis Oncology, INC. $0.72 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Meher Burki

$3,850.00

in general payments reported 2019-2025

Years
2019-2024
Top company
Cti Biopharma Corp.

https://glasscript.com/doctor/235676/meher-burki

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.